antiviral drugs

Paxlovid, the most effective Covid drug to date has its share of critics. But is the criticism fair? Drs. Henry Miller (an ACSH advisor) and Josh Bloom examine the benefits and limitations of the drug.
News organizations have recently been down on Paxlovid, while it has become the standard of care. Some claim Pfizer's Covid drug "has lost its luster" because of "failures" in two clinical trials. Now, a third trial looks like it could deliver another black mark: the drug doesn't improve symptoms in low-risk patients with Covid. Is this criticism valid? Let's look a little deeper.
There's been a lot of news, some of it fear-mongering, about Pfizer's Covid drug Paxlovid. Some people are having their symptoms return after completing the five-day course. Does that mean there is something wrong with the drug, or it's simply a property of the virus? Drs. Henry Miller and Josh Bloom try to provide an answer in Issues & Insights.
A recent study showed that Pfizer's Paxlovid, the most effective Covid drug, failed to prevent infection when given to people who were exposed to the virus but had not yet become infected. Bad news, right? Actually, no - it's quite the opposite. Here's why.
A Boston Globe article describes COVID-19 patients completing a course of Paxlovid – and then becoming ill again shortly thereafter. Is there something wrong with the drug? Is this something to worry about?
Two months ago, there was a mad rush to get the two oral antiviral pills approved to treat COVID-19. Pharmacies often ran out of these drugs within hours of delivery. Now, no one wants them. What is going on?
Should the COVID drug Paxlovid be available without a prescription? Some argue that pharmacists should be able to distribute the drug to people who have tested positive for COVID while others, including the AMA, believe that only physicians should be able to prescribe the drug because of some potentially dangerous drug-drug interactions. Cato Institute's Dr. Jeffrey Singer weighs in.
The Biden administration announced a "test to treat" plan to provide easy access to Paxlovid – an effective COVID antiviral drug – for anyone who's infected. It's not perfect, but it's sorely needed.
It's been an interesting month COVID-wise. The COVID antivirals made their way to pharmacies. All in all, things went pretty well (unless you happen to be Merck). Here, you'll learn how to locate pharmacies in your area that have been selected to carry the drugs, and how to see if the pills are in stock.
Finally, there are antiviral drugs that will keep people with COVID out of the hospital (and the morgue). But, good luck getting a prescription if you should need it. The FDA has pretty much guaranteed that this will be almost impossible. Here's why.
Emergency Use Authorization (EUA) from the FDA is the exception, not the rule. Except for COVID therapies. Three vaccines and one drug have EUA in the US. Merck is now seeking EUA for its antiviral drug molnupiravir. Should it be granted?
The New York Times (correctly) reports that a COVID pill is needed, not just a vaccine. But the paper also tells this story in its typically biased manner, implying that the government, not drug companies, discover drugs. It's a bunch of nonsense that dates back to... forever.